#news #biotech Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M .Eli Lilly & Co. is looking to pad out its diabetes portfolio by licensing an oral, nonpeptidic GLP-1 receptor agonist from Chugai Pharmaceutical that the company describes as a “phase 1 ready” asset for the treatment of Type 2 disease.

from FierceBiotech: Biotech https://ift.tt/2NP46wV